M&A / Deals Teva makes its first M&A play in years, buying Emalex PharmaphorumTeva has made its first pipeline-building acquisition in almost a decade, buying Tourette syndrome drug developer Emalex for up to $900m.Read full story pharminent April 30, 2026 (Last updated: April 30, 2026) Pharmaphorum Teva has made its first pipeline-building acquisition in almost a decade, buying Tourette syndrome drug developer Emalex for up to $900m. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolioNext: Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
